Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan. On June 23, 2026, she exercised options for 25,000 shares of common stock at $0.7132 per share, then sold 25,000 shares at an average price of $5.0157 in an open-market transaction.
Both the option exercise and the sale were carried out pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, the filing shows 0 shares of common stock held directly and no remaining listed derivative positions.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock. The shares were sold at a weighted average price of $4.1604 per share, within a range from $4.14 to $4.235 per share.
After this transaction, Barber directly holds 635,574 shares of Aquestive Therapeutics common stock.
AQST submitted a Form 144 reporting the proposed sale of 25,000 restricted stock units originally granted on 03/09/2024. The filing also discloses a Rule 10b5-1 sale by Daniel R. Barber of 8,257 common shares on 05/15/2026 for $35,413.45.
Aquestive Therapeutics director Timothy E. Morris received a grant of 50,500 stock options. These options give him the right to buy 50,500 shares of common stock at an exercise price of $3.99 per share. The options expire on June 10, 2036.
All of the underlying shares vest on June 10, 2027, provided Mr. Morris remains in continuous service with the company through that date. This is a compensation-related award rather than an open-market stock purchase or sale.
Aquestive Therapeutics director Julie Krop received a compensation-related stock option grant. She was awarded options to purchase 50,500 shares of Common Stock at an exercise price of $3.99 per share, expiring on June 10, 2036.
All 50,500 underlying shares vest 100% on June 10, 2027, subject to Dr. Krop’s continuous service with Aquestive Therapeutics through that date. After this grant, she holds 50,500 stock options directly, and the filing reports no share sales or open-market purchases.
Aquestive Therapeutics director Abigail L. Jenkins received an equity award of non-qualified stock options for 50,500 shares of common stock. The options have an exercise price of $3.99 per share, expire on June 10, 2036, and represent her direct holdings of this option grant.
All 50,500 underlying shares vest on June 10, 2027, provided she remains in continuous service with the company through that date. This is a compensation-related grant, not an open-market purchase or sale, so it mainly updates her potential future ownership rather than reflecting a trading decision.
Aquestive Therapeutics director John Cochran received a grant of 50,500 stock options on Common Stock as compensation. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he continues serving the company through that date.
Following this filing, Cochran directly holds 99,486 shares of Common Stock, separate from the new option award. The grant increases his potential future equity exposure but involves no open-market buying or selling of shares at this time.
Aquestive Therapeutics director Gregory B. Brown reported an equity compensation award. He received a grant of stock options covering 50,500 shares of Common Stock at an exercise price of $3.99 per share.
The options vest 100% on June 10, 2027, subject to his continuous service with the company through that date. Following this report, he directly holds 75,085 shares of Common Stock and the newly granted 50,500 stock options.
Aquestive Therapeutics director Marco Taglietti received a grant of stock options covering 50,500 shares of common stock. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he remains in continuous service through that date.